Biosimilar Rules Likely To Survive ACA Battle, Lawyers Say

By Bill Wichert (March 2, 2017, 10:34 PM EST) -- Amid the ongoing uncertainty over the future of the Affordable Care Act, its provisions for licensing biosimilar products will likely remain in place in light of concerns over escalating drug prices and the hard-fought battle leading to the regulations, lawyers said Thursday at a New Jersey symposium....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!